Allogene Therapeutics pursues early cancer relapse detection in LBCL with ALPHA3 trial integrating MRD testing

Allogene Therapeutics pursues early cancer relapse detection in LBCL with ALPHA3 trial integrating MRD testing
Allogene targets early LBCL relapse

One in three patients with large B-cell lymphoma (LBCL) experience cancer recurrence after receiving first-line treatment, according to Allogene Therapeutics.

The company is advancing its ALPHA3 clinical trial, which combines investigational minimal residual disease (MRD) testing technology and an off-the-shelf CAR-T product, aiming to enable earlier intervention and potentially improve cure rates for patients. The ALPHA3 study seeks to address a critical unmet need by using MRD diagnostics to identify relapses sooner in the treatment process.

Allogene is pursuing wider access to off-the-shelf CAR T cell therapy for LBCL patients with early ALPHA3 trial results, according to a previous report. The company aims to expand the reach of CAR T technology through its investigational AlloCAR T platform, as detailed in an earlier announcement. Both initiatives focus on developing alternatives to autologous CAR T treatments.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.